MTM Investment Management LLC Reduces Stake in Johnson & Johnson (NYSE:JNJ)

MTM Investment Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 6.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,683 shares of the company’s stock after selling 677 shares during the period. MTM Investment Management LLC’s holdings in Johnson & Johnson were worth $1,637,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in JNJ. Norges Bank bought a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $4,390,037,000. GAMMA Investing LLC raised its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock worth $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock worth $1,149,536,000 after buying an additional 4,559,147 shares during the last quarter. Finally, Northern Trust Corp increased its position in Johnson & Johnson by 12.3% during the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock valued at $4,456,201,000 after buying an additional 3,363,235 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.0%

Shares of NYSE:JNJ opened at $156.91 on Tuesday. The stock’s 50-day simple moving average is $153.79 and its two-hundred day simple moving average is $154.63. The stock has a market capitalization of $377.55 billion, a price-to-earnings ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The company had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. Analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. Morgan Stanley reaffirmed an “underperform” rating on shares of Johnson & Johnson in a research report on Thursday. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. The Goldman Sachs Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Finally, Raymond James Financial reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a research report on Monday, April 14th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.